All In Biotech

NDA 017744 · Legacy

Motofen Half-Strength

Atropine Sulfate, Difenoxin Hydrochloride · Oral

Novel

Last checked: Nov 20, 2026Latest source record: Mar 28, 2017 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1978

Jul 14, 1978

Approved uses

1

Original approval plus efficacy supplements

Registered trials

414

74 Phase 3, 30 recruiting

FAERS reports

26

15 serious, 1 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 23, 2026.

INDICATIONS AND USAGE MOTOFEN ® is indicated as adjunctive therapy in the management of acute nonspecific diarrhea and acute exacerbations of chronic functional diarrhea.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 14, 1978 Original approval · Type 1 - New Molecular Entity and Type 4 - New Combination
2 products under this application
  • MOTOFEN HALF-STRENGTH · ATROPINE SULFATE 0.025MG; DIFENOXIN HYDROCHLORIDE 0.5MG · TABLET, ORAL · Discontinued
  • MOTOFEN · ATROPINE SULFATE 0.025MG; DIFENOXIN HYDROCHLORIDE 1MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Atropine" as an intervention, any sponsor and status, largest first.

All 414 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • vomiting4
  • diarrhoea3
  • drug ineffective3
  • nausea3
  • pain3
  • product dose omission issue3
  • bone disorder2
  • fall2
  • irritable bowel syndrome2
  • product availability issue2
  • abdominal distension1
  • abdominal pain1

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20043
20052
20061
20071
20111
20131
20161
20175
20191
20202
20212
20223
20253

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Motofen (Difenoxin HCl/Atropine Sulfate)

2024 spending

$574K

Beneficiaries

139

672 claims

Per beneficiary

$4,128

$6.75 per unit

View as table
YearSpending
2020$857,454
2021$786,722
2022$707,800
2023$616,328
2024$573,746

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,885 on PubMed

Sponsor: Legacy · Also marketed as Motofen

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.